AR126733A1 - Inhibidores de nicotinamida ripk1 - Google Patents
Inhibidores de nicotinamida ripk1Info
- Publication number
- AR126733A1 AR126733A1 ARP220102125A ARP220102125A AR126733A1 AR 126733 A1 AR126733 A1 AR 126733A1 AR P220102125 A ARP220102125 A AR P220102125A AR P220102125 A ARP220102125 A AR P220102125A AR 126733 A1 AR126733 A1 AR 126733A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- hydrogen
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231590P | 2021-08-10 | 2021-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126733A1 true AR126733A1 (es) | 2023-11-08 |
Family
ID=83439074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102125A AR126733A1 (es) | 2021-08-10 | 2022-08-08 | Inhibidores de nicotinamida ripk1 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11767310B2 (https=) |
| EP (2) | EP4643949A3 (https=) |
| JP (2) | JP7406672B2 (https=) |
| KR (2) | KR20240135076A (https=) |
| CN (1) | CN117460722A (https=) |
| AR (1) | AR126733A1 (https=) |
| AU (1) | AU2022328136A1 (https=) |
| BR (1) | BR112023025850A2 (https=) |
| CA (1) | CA3219155A1 (https=) |
| CO (1) | CO2023017151A2 (https=) |
| IL (1) | IL308349A (https=) |
| MX (1) | MX2023014817A (https=) |
| TW (1) | TW202321211A (https=) |
| WO (1) | WO2023018643A1 (https=) |
| ZA (1) | ZA202310682B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117460722A (zh) | 2021-08-10 | 2024-01-26 | 艾伯维公司 | 烟酰胺ripk1抑制剂 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9606546A (pt) | 1995-08-02 | 1998-07-14 | Uriach & Cia Sa J | Novas carboxamidas com atividade fungicida |
| US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
| US6723727B1 (en) | 1996-12-20 | 2004-04-20 | Hoechst Aktiengesellschaft | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
| EP1664026B1 (en) | 2003-08-15 | 2009-01-21 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2007502773A (ja) | 2003-08-15 | 2007-02-15 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害薬 |
| US7112316B1 (en) | 2005-08-08 | 2006-09-26 | Uop Llc | Process for preparing molecular sieves via continuous addition of nutrients |
| EP1984355A2 (en) | 2006-02-16 | 2008-10-29 | Takeda Pharmaceutical Company Limited | Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension |
| AU2008302746B2 (en) | 2007-09-20 | 2014-07-03 | Amgen Inc. | 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders |
| ES2524883T3 (es) | 2008-03-18 | 2014-12-15 | Merck Sharp & Dohme Corp. | 4-Hidroxipirimidina-5-carboxamidas sustituidas |
| US9278922B2 (en) | 2009-04-15 | 2016-03-08 | Abbvie Inc. | Anti-viral compounds |
| US8653172B2 (en) | 2010-03-17 | 2014-02-18 | Exxonmobil Chemical Patents Inc. | Plasticiser blends and compositions and articles made therefrom |
| JP5947307B2 (ja) | 2010-10-20 | 2016-07-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｋｃｎｑ２／３調節因子としての置換６−アミノ−ニコチンアミド |
| WO2013049255A1 (en) | 2011-09-26 | 2013-04-04 | Vanderbilt University | Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors |
| TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| GEAP201814220A (en) | 2013-12-24 | 2018-03-12 | Oncotartis Inc | Benzamide and nicotinamide compounds and methods of using same |
| KR101555033B1 (ko) | 2014-07-28 | 2015-09-23 | 충남대학교산학협력단 | 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물 |
| KR101551313B1 (ko) | 2014-07-28 | 2015-09-09 | 충남대학교산학협력단 | 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물 |
| CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| WO2016101885A1 (en) | 2014-12-24 | 2016-06-30 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| EP3317269B1 (en) | 2015-07-02 | 2022-09-21 | F. Hoffmann-La Roche AG | Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases |
| AU2016340527B2 (en) | 2015-10-23 | 2020-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2017096301A1 (en) | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1) |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| IL287136B2 (en) | 2016-02-05 | 2023-09-01 | Denali Therapeutics Inc | Receptor inhibitors - interacting with protein kinase 1 |
| JP7121731B2 (ja) | 2016-09-26 | 2022-08-18 | タフツ・ユニバーシティ | ウリジンヌクレオシド誘導体、組成物及び使用方法 |
| EP3580220B1 (en) | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| DE102017211104B3 (de) | 2017-06-29 | 2018-10-18 | Bundesdruckerei Gmbh | Verfahren und Vorrichtung zum Verifizieren eines elektrolumineszierenden Sicherheitsmerkmals in einem Wert- oder Sicherheitsdokument unter Ausnutzung von zusätzlicher Lichtstrahlung |
| HRP20231381T1 (hr) | 2018-05-03 | 2024-03-01 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| JP7162372B2 (ja) * | 2018-07-02 | 2022-10-28 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのアルキニル（ヘテロ）芳香族化合物 |
| WO2020013531A1 (ko) | 2018-07-10 | 2020-01-16 | 보로노이바이오 주식회사 | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
| WO2020149553A1 (ko) * | 2019-01-15 | 2020-07-23 | 주식회사 보로노이 | 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
| CN117460722A (zh) | 2021-08-10 | 2024-01-26 | 艾伯维公司 | 烟酰胺ripk1抑制剂 |
-
2022
- 2022-08-08 CN CN202280041334.6A patent/CN117460722A/zh active Pending
- 2022-08-08 WO PCT/US2022/039689 patent/WO2023018643A1/en not_active Ceased
- 2022-08-08 BR BR112023025850A patent/BR112023025850A2/pt unknown
- 2022-08-08 IL IL308349A patent/IL308349A/en unknown
- 2022-08-08 EP EP25189687.4A patent/EP4643949A3/en active Pending
- 2022-08-08 MX MX2023014817A patent/MX2023014817A/es unknown
- 2022-08-08 CA CA3219155A patent/CA3219155A1/en active Pending
- 2022-08-08 JP JP2023516136A patent/JP7406672B2/ja active Active
- 2022-08-08 AR ARP220102125A patent/AR126733A1/es not_active Application Discontinuation
- 2022-08-08 TW TW111129732A patent/TW202321211A/zh unknown
- 2022-08-08 AU AU2022328136A patent/AU2022328136A1/en active Pending
- 2022-08-08 KR KR1020247029687A patent/KR20240135076A/ko active Pending
- 2022-08-08 EP EP22777032.8A patent/EP4301744A1/en not_active Withdrawn
- 2022-08-08 US US17/882,709 patent/US11767310B2/en active Active
- 2022-08-08 KR KR1020237038931A patent/KR102707109B1/ko active Active
-
2023
- 2023-11-17 ZA ZA2023/10682A patent/ZA202310682B/en unknown
- 2023-12-11 CO CONC2023/0017151A patent/CO2023017151A2/es unknown
- 2023-12-14 JP JP2023210859A patent/JP2024037892A/ja active Pending
-
2024
- 2024-03-18 US US18/608,389 patent/US20240360099A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4643949A3 (en) | 2026-01-07 |
| CO2023017151A2 (es) | 2023-12-29 |
| WO2023018643A1 (en) | 2023-02-16 |
| IL308349A (en) | 2024-01-01 |
| KR102707109B1 (ko) | 2024-09-20 |
| CA3219155A1 (en) | 2023-02-16 |
| EP4301744A1 (en) | 2024-01-10 |
| TW202321211A (zh) | 2023-06-01 |
| CN117460722A (zh) | 2024-01-26 |
| ZA202310682B (en) | 2024-08-28 |
| JP2024037892A (ja) | 2024-03-19 |
| KR20240135076A (ko) | 2024-09-10 |
| JP7406672B2 (ja) | 2023-12-27 |
| JP2023549007A (ja) | 2023-11-22 |
| AU2022328136A1 (en) | 2023-11-30 |
| US11767310B2 (en) | 2023-09-26 |
| US20240360099A1 (en) | 2024-10-31 |
| US20230127127A1 (en) | 2023-04-27 |
| MX2023014817A (es) | 2024-01-12 |
| BR112023025850A2 (pt) | 2024-03-05 |
| EP4643949A2 (en) | 2025-11-05 |
| KR20230163568A (ko) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114254A1 (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
| AR109349A1 (es) | Compuestos y usos | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR090191A1 (es) | Derivados del acido fenil alcanoico como agonistas gpr | |
| AR094790A1 (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| PE20212327A1 (es) | Ciertos compuestos de pladienolida y metodos de uso | |
| AR119140A1 (es) | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas | |
| AR055041A1 (es) | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. | |
| AR126733A1 (es) | Inhibidores de nicotinamida ripk1 | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh | |
| AR118641A1 (es) | Compuestos, composiciones y métodos | |
| AR120324A1 (es) | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica | |
| AR125365A1 (es) | Derivados de 1h-pirazol como ligandos sigma | |
| AR088639A1 (es) | Composicion farmaceutica oftalmica, compuestos antimicrobianos a base de carbolina | |
| AR046617A1 (es) | Compuestos inhibidores de selectina | |
| AR100126A1 (es) | Activadores de herg policíclicos | |
| AR120169A1 (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 | |
| AR127185A1 (es) | Compuestos de pirazolopiridina como inhibidores de tam | |
| AR110252A1 (es) | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |